
Sign up to save your podcasts
Or


In this minisode, Mindy, Ryan, and Jen discuss a few recent newsworthy items including: the Biden administration’s interim final rule banning surprise billing (00:35), Walmart’s launch of a private band insulin analog (04:21), and interim trial results for in vivo CRISPR-based genome editing candidate NTLA-2001 (07:00).
Podcast Tags: surprise billing, health insurance, diabetes, drug prices, gene therapy, CRISPR, healthcare, healthcare news
Source Links:
· https://www.fiercehealthcare.com/payer/biden-admin-releases-first-interim-final-rule-to-ban-surprise-medical-bills-sets?mkt_tok=ODUwLVRBQS01MTEAAAF-ELDJl4M5DBFZ7_MJTdaVw2W_WtZeiSWcn
· https://www.beckershospitalreview.com/finance/cms-unveils-surprise-billing-rule-10-things-to-know.html
· https://www.fiercehealthcare.com/finance/walmart-teams-novo-nordisk-to-launch-private-band-analog-insulin?utm_medium=nl&utm_source=internal&mrkid=65631392&mkt_tok=Mjk0LU1RRi0wNTYAAAF9_AB9bhrYERn_F0_Z_CFgnxi3JFoDbFYYjLV3ub090Lsk6j0dRKGECO_qGldwPtxlXqbfHOT4W09v3LzWGRKpmSFxz_j8dNYwt3sqlB5Nr4esKYBRlg
· https://www.statnews.com/pharmalot/2021/06/29/walmart-insulin-novo-nordisk-diabetes/?mkt_tok=ODUwLVRBQS01MTEAAAF9-91CzqJAe-LL33Gy4FjrwKJDFCfhES48aNg7kB7S_naKvfyJrEjqeHn8s6J5z34wAaGJdW4uvctwaadx9b64EBOjreZh8VfoIbEaDj06GnUa
· https://www.fiercebiotech.com/biotech/first-human-trial-results-intellia-shows-world-gene-editing-has-arrived?mkt_tok=Mjk0LU1RRi0wNTYAAAF-BlNHkt2Maf8F2j4tTY34Nbfr768q_-NEJlovuUC8YR5R6kmRnizLOIUHMuBx4yD_H3cwxx1YhNslaO10Zfx505MYvFxg2Zd5w8yFVCJGLpWlyzkEjg&mrkid=65631392
· https://www.statnews.com/2021/06/26/intellia-therapeutics-ntla-2001-data/?utm_source=STATNewsletters&utm_campaign=63bbc01b83-MR_COPY_14&utm_medium=email&utm_term=0_8cab1d7961-63bbc01b83-149847573
For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.
Mindy McGrath, Healthcare Industry Learning Lead
Ryan Hummel, Executive and Head of Provider Sector
Jen Burke, Healthcare Industry Strategist
By Inizio Ignite4.9
3434 ratings
In this minisode, Mindy, Ryan, and Jen discuss a few recent newsworthy items including: the Biden administration’s interim final rule banning surprise billing (00:35), Walmart’s launch of a private band insulin analog (04:21), and interim trial results for in vivo CRISPR-based genome editing candidate NTLA-2001 (07:00).
Podcast Tags: surprise billing, health insurance, diabetes, drug prices, gene therapy, CRISPR, healthcare, healthcare news
Source Links:
· https://www.fiercehealthcare.com/payer/biden-admin-releases-first-interim-final-rule-to-ban-surprise-medical-bills-sets?mkt_tok=ODUwLVRBQS01MTEAAAF-ELDJl4M5DBFZ7_MJTdaVw2W_WtZeiSWcn
· https://www.beckershospitalreview.com/finance/cms-unveils-surprise-billing-rule-10-things-to-know.html
· https://www.fiercehealthcare.com/finance/walmart-teams-novo-nordisk-to-launch-private-band-analog-insulin?utm_medium=nl&utm_source=internal&mrkid=65631392&mkt_tok=Mjk0LU1RRi0wNTYAAAF9_AB9bhrYERn_F0_Z_CFgnxi3JFoDbFYYjLV3ub090Lsk6j0dRKGECO_qGldwPtxlXqbfHOT4W09v3LzWGRKpmSFxz_j8dNYwt3sqlB5Nr4esKYBRlg
· https://www.statnews.com/pharmalot/2021/06/29/walmart-insulin-novo-nordisk-diabetes/?mkt_tok=ODUwLVRBQS01MTEAAAF9-91CzqJAe-LL33Gy4FjrwKJDFCfhES48aNg7kB7S_naKvfyJrEjqeHn8s6J5z34wAaGJdW4uvctwaadx9b64EBOjreZh8VfoIbEaDj06GnUa
· https://www.fiercebiotech.com/biotech/first-human-trial-results-intellia-shows-world-gene-editing-has-arrived?mkt_tok=Mjk0LU1RRi0wNTYAAAF-BlNHkt2Maf8F2j4tTY34Nbfr768q_-NEJlovuUC8YR5R6kmRnizLOIUHMuBx4yD_H3cwxx1YhNslaO10Zfx505MYvFxg2Zd5w8yFVCJGLpWlyzkEjg&mrkid=65631392
· https://www.statnews.com/2021/06/26/intellia-therapeutics-ntla-2001-data/?utm_source=STATNewsletters&utm_campaign=63bbc01b83-MR_COPY_14&utm_medium=email&utm_term=0_8cab1d7961-63bbc01b83-149847573
For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.
Mindy McGrath, Healthcare Industry Learning Lead
Ryan Hummel, Executive and Head of Provider Sector
Jen Burke, Healthcare Industry Strategist